Parathyroid hormone measurement in chronic kidney disease an evolving issue for the nephrologist and the clinical laboratorist: Minireview

Immunopharmacology and Immunotoxicology

Volumn 34, Issue 4, 2012, Pages 541-547

  Correale, Mario ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Chronic kidney disease; Immunoassays; Mineral and bone disorders; Parathyroid hormone; PTH fragments

Indexed keywords

CALCITONIN; CALCIUM; CYCLIC AMP; INOSITOL TRISPHOSPHATE; MAGNESIUM; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PHOSPHORUS; PROTEIN KINASE C; VITAMIN D;

BONE DISEASE; BONE METABOLISM; BONE TURNOVER; CHRONIC KIDNEY DISEASE; HEALTH CARE QUALITY; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; NEPHROLOGIST; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL; REVIEW;

CALCIUM; CHRONIC DISEASE; HOMEOSTASIS; HUMANS; KIDNEY DISEASES; PARATHYROID GLANDS; PARATHYROID HORMONE;

EID: 84863787045     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2011.637501     Document Type: Review

References (48)

1. Friedman, P.A., Goodman, W.G. PTH(1-84)/PTH(7-84): A balance of power. Am J Physiol Renal Physiol 2006, 290, 975-984.
2. Urena Torres, P. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006, 70, 240-243.
3. Riccardi, D., Brown, E.M. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol 2010, 298, 485-499.
4. Brown, E.M. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 2007, 3, 122-133.
5. Murray, T.M., Rao, L.G., Divieti, P., Bringhurst, F.R. Parathyroid hormone secretion and action: Evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr Rev 2005, 26, 78-113.
6. Usdin, T.B., Bonner, T.I., Hoare, S.R. The parathyroid hormone 2 (PTH2) receptor. Recept Channels 2002, 8, 211-218.
7. Brown EM. (2001). Physiology of calcium homeostasis. In: Bilezikian JP, Marcus R, Levine A. eds. The parathyroids. Second edition. Chapter 10. San Diego, USA: Academic Press Inc. pp: 167-182.
8. Ma, Y.L., Cain, R.L., Halladay, D.L., Yang, X., Zeng, Q., Miles, R.R., Chandrasekhar, S., Martin, T.J., Onyia, J.E. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001, 142, 4047-4054.
9. Deftos L. Calcium and phosphate homeostasis (updated May 17, 2010). In: Arnold A, ed. Diseases of bone and mineral metabolism. Available at: Http://www.endotext.org. Accessed on 31 August 2011.
10. Qin, L., Raggatt, L.J., Partridge, N.C. Parathyroid hormone: A double-edged sword for bone metabolism. Trends Endocrinol Metab 2004, 15, 60-65.
11. Levey, A.S., Atkins, R., Coresh, J., Cohen, E.P., Collins, A.J., Eckardt, K.U., Nahas, M.E., Jaber, B.L., Jadoul, M., Levin, A., Powe, N.R., Rossert, J., Wheeler, D.C., Lameire, N., Eknoyan, G. Chronic kidney disease as a global public health problem: Approaches and initiatives- A position statement from kidney disease improving global outcomes. Kidney Int 2007, 72, 247-259.
12. London, G., Coyne, D., Hruska, K., Malluche, H.H., Martin, K.J. The new kidney disease: Improving global outcomes (KDIGO) guidelines-expert clinical focus on bone and vascular calcification. Clin Nephrol 2010, 74, 423-432.
13. Moe, S., Drüeke, T., Cunningham, J., Goodman, W., Martin, K., Olgaard, K., Ott, S., Sprague, S., Lameire, N., Eknoyan, G. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int 2006, 69, 1945-1953.
14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney diseasemineral and bone disorder (CKD-MBD). Kidney Int 2009, 76, 1-130.
15. National Kidney Foundation. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42, 1-200.
16. Morrone L.G. Russo D. Di Iorio B. Diagnostic workup for isorders of bone and mineral metabolism in patients with chronic kidney disease in the era of KDIGO guidelines Int. J. Nephrol. 2011 art ID 958798 6 pages.
17. Morrone LG, Russo D, Di Iorio B. Diagnostic workup for disorders of bone and mineral metabolism in patients with chronic kidney disease in the era of KDIGO guidelines. Int J Nephrol 2011 art ID 958798, 6 pages. 17. Pontoriero, G., Cozzolino, M., Locatelli, F., Brancaccio, D. CKD patients: The dilemma of serum PTH levels. Nephron Clin Pract 2010, 116, c263-c268.
18. Drueke TB. Hyperparathyroidism in chronic kidney disease. (updated 1 October 2009). In: Arnold A, ed. Diseases of bone and mineral metabolism. Available at: Http://www.endotext.org. Accessed on 31 August 2011.
19. Block, G.A., Klassen, P.S., Lazarus, J.M., Ofsthun, N., Lowrie, E.G., Chertow, G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15, 2208-2218.
20. Cunningham, J., Silver, J. CKD-MBD: Comfort in the trough of the U. Nephrol Dial Transplant 2011, 26, 1764-1766.
21. Cantor, T., Yang, Z., Caraiani, N., Ilamathi, E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: Implication for treatment decisions. Clin Chem 2006, 52, 1771-1776.
22. Souberbielle, J.C., Roth, H., Fouque, D.P. Parathyroid hormone measurement in CKD. Kidney Int 2010, 77, 93-100.
23. Joly, D., Drueke, T.B., Alberti, C., Houillier, P., Lawson-Body, E., Martin, K.J., Massart, C., Moe, S.M., Monge, M., Souberbielle, J.C. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: A cross-sectional study. Am J Kidney Dis 2008, 51, 987-995.
24. Souberbielle, J.C., Friedlander, G., Cormier, C. Practical considerations in PTH testing. Clin Chim Acta 2006, 366, 81-89.
25. Cavalier, E., Delanaye, P., Carlisi, A., Krzesinski, J.M., Chapelle, J.P. Stability of intact parathyroid hormone in samples from hemodialysis patients. Kidney Int 2007, 72, 370-372.
26. Marangella, M. PTH measurement: Where do we stand?. G Ital Nefrol 2009, 26, 600-607.
27. D'Amour, P., Brossard, J.H., Rousseau, L., Roy, L., Gao, P., Cantor, T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003, 49, 2037-2044.
28. D'Amour, P., Räkel, A., Brossard, J.H., Rousseau, L., Albert, C., Cantor, T. Acute regulation of circulating parathyroid hormone (PTH) molecular forms by calcium: Utility of PTH fragments/ PTH(1-84) ratios derived from three generations of PTH assays. J Clin Endocrinol Metab 2006, 91, 283-289.
29. D'Amour, P., Brossard, J.H. Carboxyl-terminal parathyroid hormone fragments: Role in parathyroid hormone physiopathology. Curr Opin Nephrol Hypertens 2005, 14, 330-336.
30. Carrozza C, Iavarone F, Gervasoni J, Zuppi C. Problematiche del dosaggio del paratormone: Valutazione del kit access intact PTH. Ligand Assay 2008, 13, 34-39.
31. Nussbaum, S.R., Zahradnik, R.J., Lavigne, J.R., Brennan, G.L., Nozawa-Ung, K., Kim, L.Y., Keutmann, H.T., Wang, C.A., Potts, J.T. Jr, Segre, G.V. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987, 33, 1364-1367.
32. Lepage, R., Roy, L., Brossard, J.H., Rousseau, L., Dorais, C., Lazure, C., D'Amour, P. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998, 44, 805-809.
33. Slatopolsky, E., Finch, J., Clay, P., Martin, D., Sicard, G., Singer, G., Gao, P., Cantor, T., Dusso, A. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000, 58, 753-761.
34. Souberbielle, J.C., Boutten, A., Carlier, M.C., Chevenne, D., Coumaros, G., Lawson-Body, E., Massart, C., Monge, M., Myara, J., Parent, X., Plouvier, E., Houillier, P. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 2006, 70, 345-350.
35. Souberbielle, J.C., Cavalier, E., Jean, G. Interpretation of serum parathyroid hormone concentrations in dialysis patients: What do the KDIGO guidelines change for the clinical laboratory? Clin Chem Lab Med 2010, 48, 769-774.
36. John, M.R., Goodman, W.G., Gao, P., Cantor, T.L., Salusky, I.B., Jüppner, H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999, 84, 4287-4290.
37. Gao, P., Scheibel, S., D'Amour, P., John, M.R., Rao, S.D., Schmidt- Gayk, H., Cantor, T.L. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001, 16, 605-614.
38. Räkel, A., Brossard, J.H., Patenaude, J.V., Albert, C., Nassif, E., Cantor, T., Rousseau, L., D'Amour, P. Overproduction of an aminoterminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: Influence of medical treatment and surgery. Clin Endocrinol (Oxf ) 2005, 62, 721-727.
39. Taniguchi, M., Tanaka, M., Hamano, T., Nakanishi, S., Fujii, H., Kato, H., Koiwa, F., Ando, R., Kimata, N., Akiba, T., Kono, T., Yokoyama, K., Shigematsu, T., Kakuta, T., Kazama, J.J., Tominaga, Y., Fukagawa, M. Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial 2011, 15, 42-49.
40. Martin, K.J., Jüppner, H., Sherrard, D.J., Goodman, W.G., Kaplan, M.R., Nassar, G., Campbell, P., Curzi, M., Charytan, C., McCary, L.C., Guo, M.D., Turner, S.A., Bushinsky, D.A. First- and secondgeneration immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 2005, 68, 1236-1243.
41. Melamed, M.L., Eustace, J.A., Plantinga, L.C., Jaar, B.G., Fink, N.E., Parekh, R.S., Coresh, J., Yang, Z., Cantor, T., Powe, N.R. Thirdgeneration parathyroid hormone assays and all-cause mortality in incident dialysis patients: The CHOICE study. Nephrol Dial Transplant 2008, 23, 1650-1658.
42. Cavalier, E., Daly, A.F., Betea, D., Pruteanu-Apetrii, P.N., Delanaye, P., Stubbs, P., Bradwell, A.R., Chapelle, J.P., Beckers, A. The ratio of parathyroid hormone as measured by third- and secondgeneration assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 2010, 95, 3745-3749.
43. Caron, P., Simonds, W.F., Maiza, J.C., Rubin, M., Cantor, T., Rousseau, L., Bilezikian, J.P., Souberbielle, J.C., D'Amour, P. Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: A possible link to HRPT2 gene inactivation. Clin Endocrinol (Oxf ) 2011, 74, 694-698.
44. Cavalier E, Rousselle AO, Bekaert AC, Carlisi A, Chapelle JP, Delanaye P. Evaluation of Diasorin Liaison 1-84 PTH assay, a new automated immunoassay for the determination of 3rd generation PTH. AACC Annual Meeting 2010 abstract.
45. Zanelli, J.M., Gaines-Das, R.E. The first international reference preparation of human parathyroid hormone for immunoassay: Characterization and calibration by international collaborative study. J Clin Endocrinol Metab 1983, 57, 462-469.
46. Rej, R., Drake, P. The nature of calibrators in immunoassays: Are they commutable with test samples? must they be? Scand J Clin Lab Invest Suppl 1991, 205, 47-54.
47. WHO Document from Expert Committee on Biological Standardization, Geneva, 19 to 23 October 2009. WHO/BS/09.2115.
48. Souberbielle, J.C., Cormier, C., Kindermans, C., Gao, P., Cantor, T., Forette, F., Baulieu, E.E. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 2001, 86, 3086-3090.